All Clinical Trials
Filter by Category
- All Clinical Trials
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
Official Title An Interferon-Free Antiviral Regimen for HCV After Liver Transplantation
Phase Phase II
ClinicalTrials.gov NCT01782495
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-82.
Official Title Effectiveness, Treatment Completion and Safety of Sofosbuvir-Ledipasvir and Paritaprevir-Ritonavir-Ombitasvir plus Dasabuvir in Patients with Chronic Kidney Disease: an ERCHIVES Study.
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryGilead Sciences
Non-IndustryVA Pittsburgh Healthcare System.
References
- Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018;48:35-43.
Official Title ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response with or without Ribavirin in Treatment-Experienced Patients with HCV Genotype 1b Infection
Phase Phase III
ClinicalTrials.gov NCT01674725
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359-6.5
Official Title ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Phase Phase III
ClinicalTrials.gov NCT01767116
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-92.
Official Title Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
Phase Phase III
ClinicalTrials.gov NCT02207088
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology. 2016;150:1590-8.
Official Title Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin.
Phase Phase III
ClinicalTrials.gov NCT01716585
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-603.
Official Title Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Phase Phase III
ClinicalTrials.gov NCT01715415
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Zeuzem S, Jacobson IM, Baykai T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604-14.
Official Title Ombitasvir, Paritaprevir Co-Dosed with Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients co-Infected with HIV-1: a Randomized Trial.
Phase Phase III
ClinicalTrials.gov NCT01939197
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223-31.
Official Title ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Phase Phase III
ClinicalTrials.gov NCT01704755
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-82.
Official Title Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks
Phase Phase III
ClinicalTrials.gov NCT02219503
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie
References
- Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016;64:301-307.